Search

Despite efforts to prevent new HIV infections, more than 27 000 people were newly diagnosed with HIV in the European Union (EU) and the European Economic Area (EEA) in 2010.

This joint guidance from ECDC and the European Monitoring Centre for Drugs and Drug Addiction provides EU/EEA Member States with evidence-based scientific advice on active case finding options. These options can be applied to the planning and implementation of interventions that promote the early diagnosis of communicable diseases in prison settings.

This document provides EU/EEA Member States with evidence-based scientific advice on available options, when planning and implementing prevention and control interventions for blood-borne viruses in prison settings.

This guidance is intended for policymakers responsible for the planning and delivery of healthcare services in the national or sub-national custodial system and all professionals responsible for the health and well-being of people in prison, including community-based service providers and those facilitating continuity of care in the community.

This guidance aims to provide EU/EEA countries with an evidence-based framework to help develop, implement, monitor and evaluate their own national HBV, HCV and HIV testing guidelines and programmes.

The ECDC guidance on integrated testing of hepatitis B (HBV), hepatitis C (HCV) and HIV supports countries in the global effort to combat viral hepatitis and eliminate HIV as public health threats by 2030. At present, reaching and testing those at risk of infection with HIV, HBV or HCV is still a public health challenge across Europe. This Guidance in brief is based on the comprehensive guidance document which provides the evidence base for this guidance

This guidance, based on a systematic review of the literature and expert opinion, suggests that there is good evidence to ensure that some key components are considered for inclusion in national and sub-national public health programmes in countries in Europe.

This publication aims to support the strengthening of antenatal screening programmes for HIV, hepatitis B, syphilis and rubella susceptibility in the general population and in groups identified as vulnerable to mother-to-child-transmission in the EU/EEA.

This document outlines the steps necessary to implement a comprehensive and effective control programme. It also offers advice on how to monitor and evaluate such programmes in order to ensure their effectiveness.

As the number of people infected with HIV continues to rise, there is increasing evidence that early treatment reduces morbidity and mortality.